Navigation Links
Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
Date:12/6/2012

SEATTLE, Dec. 6, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.  OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

In this successful SAD study, OMS824 was well tolerated and demonstrated linear pharmacokinetics, a long half-life consistent with once daily dosing and good systemic exposure that, at the highest dose administered, resulted in the expected pharmacological effects in healthy subjects.  With these encouraging data, Omeros has advanced OMS824 to the next stage of the Phase 1 clinical trial – the evaluation of multiple-dose administration of the compound.  Omeros expects complete data to be available in early 2013. 

"OMS824 appears to have excellent pharmaceutical properties, and we look forward to completing this Phase 1 clinical trial and starting studies in schizophrenia patients," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "While preparing for the next set of OMS824 studies, our pipeline continues to advance toward additional near-term milestones – Phase 3 data for OMS103HP this month, an NDA submission next quarter and, for as many as three additional programs, entry into the clinic in 2013."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. Cognitive dysfunction occurs early in these diseases and is responsible for substantial disability. Omeros' proprietary compound OMS824 inhibits PDE10 a
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
2. Omeros is Not Aware of Any Justification for Share Price Movement
3. Omeros Corporation Reports Third Quarter 2012 Financial Results
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
6. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
7. Omeros to Present at Two Upcoming Conferences
8. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Discovery in MASP-2 Program
11. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Dyax Corp.,(Nasdaq:DYAX) announced today positive topline results ... its lead product,candidate DX-88 (ecallantide), for hereditary ... data is scheduled for Tuesday,April 17, 2007 ... discovered, recombinant, plasma kallikrein,inhibitor, is in clinical ...
... 2007 - In a late-breaker,presentation at the ... the Study of the Liver (EASL), researchers ... of the PROVE 1 clinical trial,which is ... with,the investigational hepatitis C protease inhibitor telaprevir ...
Cached Medicine Technology:DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 2DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 3DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 4DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... provide relief for "tennis elbow" but needs to be ... article in CMAJ ( Canadian Medical Association ... The study, a randomized controlled trial of 48 patients, ... the Tehran University of Medical Sciences that serves patients ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... to be good candidates upon death, study finds , ... developed a new tool that may help neurologists identify ... that could potentially boost organ donation rates. , Coma ... for organ donation when they die because their other ...
... high cholesterol or diabetes now widespread, CDC survey finds ... of all American adults have either high blood pressure, ... for heart disease, stroke and other cardiovascular problems, a ... the U.S. National Health and Nutrition Examination Survey (NHANES) ...
... - The American Society of Pediatric Otolaryngology (ASPO) will ... during the 2010 Combined Otolaryngology Spring Meetings (COSM) - ... Vegas, NV. During the ASPO meeting, hundreds ... sessions featuring expert panelists will be presented focusing on ...
... ... book on both sides of the Atlantic. This layman,s account of his interest and research ... self worth, regardless of historical, cultural or religious backgrounds, as it strives to touch all ... Washington, ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... Endotracheal Tube w. FlexiSlip™ Stylet, Murphy eye. Tube ... Rusch endotracheal tube with a preloaded Flexi-Slip Stylet ... storage space. The stylet has a low friction ... with a soft distal tip to reduce the ...
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Ruschelit® PVC. Murphy eye-oral. High ... Graduated. Oral Cuffed Single use. For ... kinking of the tube by incorporating ... low-pressure cuff. Thermosensitive Ruschelit® PVC adapts ...
Medicine Products: